CSF2 and melanoma: Second, in 2015, the US Food and Drug Administration (FDA) approved the granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing talimogene laherparepvec (T-VEC) HSV for the treatment of unresectable advanced melanoma [20,21,22].